公开(公告)号：US20120201861A1

公开(公告)日：2012-08-09

申请号：US13369722

申请日：2012-02-09

Applicant: Kayo NAKANO ,  Akira Sato ,  Takao Kusaka ,  Shinya Kasamatsu ,  Akito Sasaki ,  Daisuke Fukushi

Inventor： Kayo NAKANO ,  Akira Sato ,  Takao Kusaka ,  Shinya Kasamatsu ,  Akito Sasaki ,  Daisuke Fukushi

IPC: A01N59/16 ,  A01N59/20 ,  C01G41/02 ,  B32B5/16 ,  A01N25/00 ,  A01P1/00 ,  B82Y30/00 ,  B82Y99/00

CPC classification number: A01N25/12 ,  A01N59/16 ,  A61K33/24 ,  A61K33/38 ,  B01J21/063 ,  B01J21/066 ,  B01J23/30 ,  B01J23/34 ,  B01J23/6527 ,  B01J23/888 ,  B01J35/002 ,  B01J35/004 ,  B01J35/023 ,  B01J35/06 ,  B01J35/1009 ,  B01J35/1014 ,  B01J35/1019 ,  B01J35/1023 ,  B01J37/0201 ,  B01J37/0215 ,  B01J37/04 ,  B01J37/349 ,  C03C17/006 ,  C03C2217/42 ,  C03C2217/70

Abstract: In one embodiment, an antiviral material includes at least one microparticles selected from tungsten oxide microparticles and tungsten oxide composite microparticles. The microparticles have an inactivation effect R of 1 or more expressed by [R=logC−logA], when there is evaluated a virus titer by inoculating on a specimen to which the microparticles are adhered, at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1) and a swine influenza virus, and irradiating the specimen with visible light having a wavelength of 380 nm or more and illuminance of 6000 1× for 24 hours.

Abstract translation: 在一个实施方案中，抗病毒材料包括至少一种选自氧化钨微粒和氧化钨复合微粒的微粒。 当通过接种在附着有微粒的样品上的病毒滴度来评估微粒具有1或更多表达的失活效应R时，至少有一种病毒选自低致病性禽鸟 流感病毒（H9N2），高致病性禽流感病毒（H5N1）和猪流感病毒，用波长380nm以上的可见光和6000×1×的照度照射24小时。

公开(公告)号：US08741349B2

公开(公告)日：2014-06-03

申请号：US13369722

申请日：2012-02-09

Applicant: Kayo Nakano ,  Akira Sato ,  Takao Kusaka ,  Shinya Kasamatsu ,  Akito Sasaki ,  Daisuke Fukushi

Inventor： Kayo Nakano ,  Akira Sato ,  Takao Kusaka ,  Shinya Kasamatsu ,  Akito Sasaki ,  Daisuke Fukushi

IPC: A61K9/14 ,  A61K9/51

CPC classification number: A01N25/12 ,  A01N59/16 ,  A61K33/24 ,  A61K33/38 ,  B01J21/063 ,  B01J21/066 ,  B01J23/30 ,  B01J23/34 ,  B01J23/6527 ,  B01J23/888 ,  B01J35/002 ,  B01J35/004 ,  B01J35/023 ,  B01J35/06 ,  B01J35/1009 ,  B01J35/1014 ,  B01J35/1019 ,  B01J35/1023 ,  B01J37/0201 ,  B01J37/0215 ,  B01J37/04 ,  B01J37/349 ,  C03C17/006 ,  C03C2217/42 ,  C03C2217/70

Abstract: In one embodiment, an antiviral material includes at least one microparticles selected from tungsten oxide microparticles and tungsten oxide composite microparticles. The microparticles have an inactivation effect R of 1 or more expressed by [R=log C−log A], when there is evaluated a virus titer by inoculating on a specimen to which the microparticles are adhered, at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1) and a swine influenza virus, and irradiating the specimen with visible light having a wavelength of 380 nm or more and illuminance of 6000 1× for 24 hours.

Abstract translation: 在一个实施方案中，抗病毒材料包括至少一种选自氧化钨微粒和氧化钨复合微粒的微粒。 当通过接种在附着有微粒的样品上评价病毒滴度时，微粒具有由[R = log C-log A]表示的1或更多个的失活效应R，至少一种选自低 病原性禽流感病毒（H9N2），高致病性禽流感病毒（H5N1）和猪流感病毒，并用波长380nm以上的可见光和6000×1×的照度照射24小时。